cagrilintide semaglutide peptide CagriSema Dosage Protocol: Research Reference Data Cagrilintide: The Next-Gen Peptide for

Whilst all agents in this class can cause nausea, individual responses vary: Dulaglutide (Trulicity) is administered once weekly and some patients report fewer gastrointestinal effects Liraglutide (Victoza) requires daily injection but allows more gradual dose titration Exenatide (Byetta, Bydureon) is available in both short-acting (twice daily) and extended-release (once weekly) formulations Switching between GLP-1 agonists should be undertaken under medical supervision with appropriate dose adjustment and monitoring

Emerging uses of glucagon-like peptide 1 (GLP-1) receptor agonists following ileal resection: literature review and case examples

Zhou et al., 2016)

The appetite-suppressing effects occur through complex interactions with the central nervous system, which has led researchers to hypothesise that these medications might influence other reward-driven behaviours, including alcohol consumption